{"id":"W3157950444","doi":"10.1200/jco.20.02822","title":"Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"ca_institutions":"Seagen (Canada)","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Trastuzumab; Pertuzumab; Metastatic breast cancer; Internal medicine; Clinical endpoint; Oncology; Brain metastasis; Adverse effect; Breast cancer; Cancer; Phases of clinical research; Radiation therapy; Chemotherapy; Surgery; Metastasis; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001942755,0.0002616995,0.003654873,0.0004229867,0.00005863627,0.00001206613,0.00009929413,0.0001037817,0.0002274412],"category_scores_gemma":[0.0008031246,0.0001624249,0.0004871253,0.0009023221,0.0002887456,0.0001472201,0.00009835338,0.0005757685,3.383721e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004570105,"about_ca_system_score_gemma":0.002923509,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002206174,"about_ca_topic_score_gemma":0.0003996451,"domain_scores_codex":[0.9947249,0.001635509,0.002305791,0.0003949679,0.0006664931,0.0002723814],"domain_scores_gemma":[0.9940507,0.002286388,0.002037862,0.0002517665,0.0009984458,0.0003747672],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.05058261,0.1198002,0.4293841,0.0001209994,0.04565778,0.01246302,0.00156827,0.0003229576,0.00001935705,0.00002842722,0.0002177079,0.3398346],"study_design_scores_gemma":[0.07797869,0.08276517,0.8146833,0.000174049,0.02245715,0.0002560364,0.00130466,0.0001144039,0.00001581148,0.00001477401,0.0001125839,0.0001233669],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9934214,0.001640622,0.00005203668,0.003575908,0.0001211016,0.0007300098,0.0004334643,0.000003964201,0.00002148933],"genre_scores_gemma":[0.994584,0.0001943552,0.004005498,0.0009702541,0.00007687882,0.00002720973,0.00009249346,0.00002021041,0.00002910227],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3852992,"threshold_uncertainty_score":0.6623495,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04527426126557866,"score_gpt":0.4341522077045012,"score_spread":0.3888779464389226,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}